Safety and Immunogenicity of a 4-Component Toxoid-Based
A Venkatasubramaniam, G Liao, E Cho… - Fighting an Elusive …, 2022 - books.google.com
Staphylococcus aureus is a leading cause of significant morbidity and mortality and an
enormous economic burden to public health worldwide. Infections caused by …
enormous economic burden to public health worldwide. Infections caused by …
[HTML][HTML] Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus Macaques
A Venkatasubramaniam, G Liao, E Cho… - Frontiers in …, 2021 - frontiersin.org
Staphylococcus aureus is a leading cause of significant morbidity and mortality and an
enormous economic burden to public health worldwide. Infections caused by methicillin …
enormous economic burden to public health worldwide. Infections caused by methicillin …
[HTML][HTML] IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus
H Karauzum, A Venkatasubramaniam… - Frontiers in …, 2021 - frontiersin.org
Staphylococcus aureus causes a wide range of diseases from skin infections to life
threatening invasive diseases such as bacteremia, endocarditis, pneumonia, surgical site …
threatening invasive diseases such as bacteremia, endocarditis, pneumonia, surgical site …
[HTML][HTML] Hyperimmune targeting staphylococcal toxins effectively protect against USA 300 MRSA infection in mouse bacteremia and pneumonia models
X Han, R Ortines, I Mukherjee, T Kanipakala… - Frontiers in …, 2022 - frontiersin.org
Staphylococcus aureus has been acquiring multiple drug resistance and has evolved into
superbugs such as Methicillin/Vancomycin-resistant S. aureus (MRSA/VRSA) and …
superbugs such as Methicillin/Vancomycin-resistant S. aureus (MRSA/VRSA) and …
[HTML][HTML] Dry and liquid formulations of IBT-V02, a novel multi-component toxoid vaccine, are effective against Staphylococcus aureus isolates from low-to-middle …
Y Wang, I Mukherjee, A Venkatasubramaniam… - Frontiers in …, 2024 - frontiersin.org
Staphylococcus aureus is the leading cause of skin and soft tissue infections (SSTIs) in the
US as well as more serious invasive diseases, including bacteremia, sepsis, endocarditis …
US as well as more serious invasive diseases, including bacteremia, sepsis, endocarditis …
Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model
PN Reddy, S Paul, MH Sripathy, HV Batra - Toxicon, 2015 - Elsevier
Abstract Treatment of Staphylococcus aureus infections has become complicated owing to
growing antibiotic resistance mechanisms and due to the multitude of virulence factors …
growing antibiotic resistance mechanisms and due to the multitude of virulence factors …
Development of combination vaccine conferring optimal protection against six pore-forming toxins of Staphylococcus aureus
QF Zhang, TT Jiang, X Mao, JD Kim, DH Ahn… - Infection and …, 2021 - Am Soc Microbiol
In the Gram-positive pathogen Staphylococcus aureus, pore-forming toxins (PFTs), such as
leukocidins and hemolysins, play prominent roles in staphylococcal pathogenesis by killing …
leukocidins and hemolysins, play prominent roles in staphylococcal pathogenesis by killing …
[HTML][HTML] Staphylococcal bicomponent pore-forming toxins: targets for prophylaxis and immunotherapy
MJ Aman, RP Adhikari - Toxins, 2014 - mdpi.com
Staphylococccus aureus represents one of the most challenging human pathogens as well
as a common colonizer of human skin and mucosal surfaces. S. aureus causes a wide …
as a common colonizer of human skin and mucosal surfaces. S. aureus causes a wide …
[HTML][HTML] Superantigens of a superbug: Major culprits of Staphylococcus aureus disease?
MJ Aman - Virulence, 2017 - Taylor & Francis
Infections with multidrug resistant (MDR) bacteria represent a major challenge for public
health. Methicillin resistant S. aureus (MRSA) is one of the leading causes of hospital and …
health. Methicillin resistant S. aureus (MRSA) is one of the leading causes of hospital and …
Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial
J Levy, L Licini, E Haelterman, P Moris… - Human vaccines & …, 2015 - Taylor & Francis
We assessed the safety, reactogenicity and immunogenicity of a staphylococcal vaccine
combining capsular polysaccharides types 5 and 8 (CPS5/8), conjugated to tetanus toxoid …
combining capsular polysaccharides types 5 and 8 (CPS5/8), conjugated to tetanus toxoid …